<DOC>
	<DOCNO>NCT02604914</DOCNO>
	<brief_summary>An Open-Label Study Healthy Male Female Subjects Identify Concentration Provides Optimal Bioavailability Levodopa Infused Subcutaneously via Pump System ; Compare Bioavailability Levodopa/Carbidopa Solution Levodopa/Carbidopa Intestinal Gel ( LCIG ) , Infused via Naso-Jejunal Tube</brief_summary>
	<brief_title>A Sequential Two-Part , Open-Label Study Healthy Male Female Subjects</brief_title>
	<detailed_description>Part 1 : This single centre , open-label design 2 study arm ( ND0612H ND0612L ) , 24 subject receive ND0612L ND0612H regimen . Part subject also participate Part 2 study . Within study arm , subject receive 3 dos investigational LD/CD solution subcutaneous ( SC ) infusion . Study drug administer 24 -30 hour subcutaneous ( SC ) infusion low abdomen . Then subject readmitted Part 2 . Part 2 : This single centre , open-label design 3 treatment arm 15 subject complete ND0612H arm Part 1 ND0612-005a allocate randomised manner . Within treatment arm subject receive 2 3 dos LCIG infuse 16 hour directly jejunum . Subjects discharge clinic 24 hour end last infusion</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Part 1 ND0612005a : 1 . Healthy male nonpregnant , nonlactating healthy female 2 . Age 40 65 year age 3 . Body mass index 18.0 32.0 kg/m2 , outside range , consider clinically significant investigator 4 . Must willing able communicate participate whole study ( Part 1 subject assign ND0612L Part 1 Part 2 subject assign ND0612H ) 5 . Must provide write informed consent 6 . Area administration evaluable local skin reaction ( normal skin without skin burn , scar large tattoos area administration ) 7 . Must agree use adequate method contraception Part 2 ND0612005b : 1 . Subjects dose ND0612H ( replacement subject enrol Part 2 dose optimal LD/CD concentration ND0612H completion Part 2 ) . 1 . Participation clinical research study within previous 3 month 2 . Subjects study site employee , immediate family member study site sponsor employee 3 . Subjects previously enrol study 4 . History drug alcohol abuse past 2 year 5 . Regular alcohol consumption male &gt; 21 unit per week female &gt; 14 unit per week ( 1 unit = ½ pint beer , 25 mL 40 % spirit 125 mL glass wine ) 6 . Current smoker smoke within last 12 month . A breath carbon monoxide read great 10 ppm screen 7 . Females childbearing potential pregnant lactating ( female subject must negative urine pregnancy test admission ) 8 . Clinically significant abnormal biochemistry , haematology urinalysis judge investigator ( laboratory parameter list Appendix 1 ) 9 . Positive drug abuse test result ( drug abuse test list Appendix 1 ) 10 . Positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCV Ab ) human immunodeficiency virus ( HIV ) result 11 . Subjects suitable vein multiple venepunctures/cannulation assess investigator screen 12 . History cardiovascular , renal , hepatic , chronic respiratory GI disease judge investigator 13 . Serious adverse reaction serious hypersensitivity drug formulation excipients 14 . Presence history clinically significant allergy require treatment , judge investigator . Hayfever allow unless active 15 . Donation loss great 400 mL blood within previous 3 month 16 . Subjects take , take , prescribed overthecounter drug ( 4 g per day paracetamol , hormone replacement therapy hormonal contraception ) herbal remedy 14 day IMP administration ( See Section 11.4 ) . Exceptions may apply case case basis consider interfere objective study agree PI sponsor 's medical monitor 17 . Use nonselective monoamine oxidase ( MAO ) inhibitor within 2 week screen 18 . History presence glaucoma 19 . History presence suspicious undiagnosed skin lesion history melanoma 20 . Any history psychoses seizure 21 . Known hypersensitivity Sinemet® domperidone excipients 22 . Any history presence Prolactinreleasing pituitary tumour ( prolactinoma ) 23 . Any medical history GI haemorrhage , mechanical obstruction perforation 24 . Any history moderate severe hepatic impairment 25 . Subjects clinically significant liver function test 26 . Subjects QTc &gt; 450 m screen 27 . Subjects significant electrolyte disturbance 28 . Subjects underlie cardiac disease 29 . Subjects receive QTprolonging drug potent cytochrome P450 ( CYP ) 3A4 inhibitor within 4 week screen 30 . ND0612H arm : Subjects sinus problem 31 . ND0612H arm : Subjects regular heartburn and/or indigestion 32 . ND0612H arm : Subjects abdominal ( bowel ) surgery 33 . ND0612H arm : Any clinically significant finding observe nasojejunal tube placement determine endoscopist 34 . Failure satisfy investigator fitness participate reason</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>